Holen Sie sich die Stockscreener-App
373.46
4.03%
14.46
Handel nachbörslich:
373.46
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt MDGL?
Forum
Prognose
Aktiensplit
Madrigal Pharmaceuticals Inc Aktie (MDGL) Neueste Nachrichten
Madrigal Pharmaceuticals director sells $16.6m in stock - Investing.com
Madrigal Pharmaceuticals director Taub sells $16.5 million in stock By Investing.com - Investing.com Nigeria
Madrigal Pharmaceuticals Grants Equity Awards to New Hires Under Inducement Plan - MSN
Madrigal Pharmaceuticals to Present at Canaccord Genuity Growth Conference - MSN
Forecast: Analysts Think Madrigal Pharmaceuticals, Inc.'s (NASDAQ:MDGL) Business Prospects Have Improved Drastically - simplywall.st
S&E In Brief: Launch Updates And Political Headwinds - insights.citeline.com
Piper Sandler reiterates Overweight rating on Madrigal stock amid strong launch - Investing.com Canada
MDGL: UBS Raises Price Target Amidst Steady Buy Ratings | MDGL S - GuruFocus
Jefferies raises Madrigal Pharmaceuticals stock price target to $502 on patent extension - Investing.com Canada
Madrigal Pharmaceuticals to Participate in the Canaccord Genuity 45th Annual Growth Conference - GlobeNewswire
Madrigal (MDGL) Secures $500M to Fuel MASH Pipeline Expansion - MSN
Madrigal jumps as MASH drug Rezdiffra drives massive Q2 beat - MSN
Party Time: Brokers Just Made Major Increases To Their Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Earnings Forecasts - uk.finance.yahoo.com
Leading vs lagging indicators on Madrigal Pharmaceuticals Inc. performanceSwing Trade Watchlist with Entry Zones - Newser
What to do if you’re stuck in Madrigal Pharmaceuticals Inc.Trade Ideas Based on Fundamental Metrics - Newser
Madrigal Pharmaceuticals Q2 2025 Earnings Preview - MSN
What to expect from Madrigal Pharmaceuticals Inc. in the next 30 daysFree Consistent Income Focused Trade List - Newser
Earnings Beat: Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts - simplywall.st
Madrigal Pharmaceuticals: Strategic Growth and Market Potential Driven by Rezdiffra’s Success and Key Acquisitions - TipRanks
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Q2 2025 Earnings Call Transcript - Insider Monkey
Madrigal signals blockbuster Rezdiffra trajectory as new patent extends exclusivity to 2045 - MSN
MDGL Analyst Rating Update: Canaccord Genuity Raises Price Targe - GuruFocus
Cautious Outlook on Madrigal Pharmaceuticals: Sell Rating Amid Competitive Pressures and Valuation Concerns - TipRanks
Madrigal Pharmaceuticals (MDGL) Stock Target Raised on Strong 2Q Results - GuruFocus
Madrigal Pharmaceuticals shares fall 1.15% premarket after reporting a Q2 net loss of $42.3 million. - AInvest
Madrigal 2025 Q2 Earnings Strong Revenue Surge, Narrowed Losses - AInvest
Madrigal: Q2 Earnings Snapshot - New Haven Register
Madrigal Pharmaceuticals Inc (MDGL) Q2 2025 Earnings Call Highlights: Strong Sales Growth and ... By GuruFocus - Investing.com Canada
Madrigal (MDGL) Q2 Revenue Soars 1,313% - AOL.com
Madrigal Pharmaceuticals Reports Strong Q2 2025 Results - TipRanks
Madrigal Surges 8.59 on 290th-Ranked $410M Volume as Patent Extensions and $212M Rezdiffra Sales Drive Momentum - AInvest
Madrigal Pharmaceuticals (MDGL) Achieves Key Growth Milestones w - GuruFocus
Madrigal Pharmaceuticals' Q2 2025: Contradictions Surrounding GLP-1 Market Impact and Rezdiffra Growth - AInvest
Madrigal Pharmaceuticals stock surges as Goldman reiterates buy on strong sales - Investing.com Canada
Madrigal Pharmaceuticals to Announce Q2 2025 Results with Live Webcast - MSN
Madrigal (MDGL) Q2 Revenue Soars 1,313% - The Motley Fool
Madrigal stock jumps after massive Q2 beat (MDGL:NASDAQ) - Seeking Alpha
Madrigal’s MASH drug handily tops forecasts as execs discuss GLP-1 combos - Endpoints News
Madrigal Pharmaceuticals reports Q2 EPS ($1.90), consensus ($3.53) - TipRanks
GLP-1, Rezdiffra MASH-up eyed in $2B Madrigal/CSPC deal - BioWorld MedTech
Madrigal (MDGL) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
Madrigal Pharmaceuticals Reports Second-Quarter 2025 Financial R - GuruFocus
Madrigal Pharmaceuticals Q2 Financial Results Exceed ExpectationsNews and Statistics - IndexBox
Madrigal Pharmaceuticals Q2 Net Loss Narrows, Revenue Increases; Shares Rise - MarketScreener
Madrigal Pharma's Q2 sales surge on Rezdiffra demand - MarketScreener
Madrigal Pharmaceuticals' Q2 2025 Earnings Signal a Pivotal Moment for Long-Term Value Creation - AInvest
Earnings Flash (MDGL) Madrigal Pharmaceuticals, Inc. Reports Q2 Revenue $212.8M, vs. FactSet Est of $162.0M - MarketScreener
Madrigal Pharmaceuticals Reports $212.8 Million in Second-Quarter 2025 Net Sales for Rezdiffra™, Secures New Patent and Licensing Agreement - Quiver Quantitative
Madrigal Pharmaceuticals Reports Second-Quarter 2025 Financial Results and Provides Corporate Updates - The Manila Times
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):